Agalactia and Hypogalactia (Absence or Insufficiency of Milk Secretion)

Agalactia is the complete absence of milk secretion, while hypogalactia is a reduced or inadequate milk production in the postpartum period. In bitches and queens, these conditions are characterized by failure of the mammary glands to produce sufficient colostrum and milk to meet the nutritional and immunological needs of the neonates. The condition can be primary, due to intrinsic mammary gland dysfunction or hormonal imbalances, or secondary, resulting from maternal systemic illness, pain, stress, or drug-induced suppression. Normal lactation is initiated by a complex interplay of hormones, including a prepartum decline in progesterone, a sustained elevation of prolactin, and the release of oxytocin for milk ejection. Agalactia and hypogalactia can lead to neonatal malnutrition, hypoglycemia, hypothermia, failure of passive transfer of immunoglobulins, and increased neonatal mortality. The condition is a significant clinical entity in small animal reproduction, requiring prompt recognition and intervention to safeguard both maternal health and litter viability.

The etiologies of agalactia and hypogalactia are multifactorial. Primary causes include congenital or hereditary defects in mammary gland development (e.g., hypoplasia or aplasia of glandular tissue), endocrine imbalances such as insufficient prolactin secretion due to pituitary dysfunction, and inadequate prepartum progesterone withdrawal. Secondary causes are more common and include maternal systemic diseases such as pyometra, mastitis, metritis, eclampsia (hypocalcemia), sepsis, or any febrile illness that suppresses appetite and milk production. Pain from dystocia, cesarean section, or perineal trauma can inhibit oxytocin release, leading to failure of milk ejection (galactostasis) despite adequate milk synthesis. Stress, fear, or anxiety in a primiparous dam can also impair lactation. Iatrogenic causes include the administration of drugs that suppress prolactin, such as dopamine agonists (e.g., cabergoline, bromocriptine) used for pregnancy termination, or glucocorticoids at high doses. Nutritional deficiencies, particularly inadequate energy, protein, calcium, or water intake during gestation and lactation, can compromise milk synthesis. Additionally, obesity or poor body condition can affect hormonal profiles and mammary development. Infectious agents, such as bacteria causing mastitis (e.g., Staphylococcus spp., Streptococcus spp., Escherichia coli), can directly damage mammary tissue and reduce milk production. In queens, feline herpesvirus or feline leukemia virus infections may contribute to systemic illness and lactation failure.

Agalactia and hypogalactia are reported in both dogs and cats, with a higher incidence in primiparous females, likely due to inexperience, stress, and inadequate mammary development. Certain breeds may be predisposed due to conformational or genetic factors, such as toy and brachycephalic breeds in dogs, which often have small litters and may have poor nursing ability. In cats, pedigree breeds such as Persians and Siamese may be overrepresented. The condition can occur after both natural whelping and cesarean section, with a higher risk after surgical delivery due to pain, anesthesia, and stress. The incidence is variable, but studies suggest that up to 10-15% of bitches may experience some degree of lactation insufficiency. Risk factors include dystocia, prolonged labor, retained fetal membranes, and postpartum metritis. Environmental factors such as poor kennel hygiene, overcrowding, and lack of maternal bonding can contribute. Additionally, dams with a history of previous lactation problems are at increased risk. The condition is more common in small breeds with large litters, where the demand for milk exceeds the supply. In queens, the condition is less frequently reported but can occur, especially in first-time mothers or those with large litters.

The pathophysiology of agalactia and hypogalactia involves disruption of the normal endocrine and neuroendocrine mechanisms regulating lactation. During pregnancy, high levels of progesterone and estrogen promote mammary gland development (mammogenesis), but inhibit lactogenesis. At parturition, the abrupt decline in progesterone, along with elevated prolactin and glucocorticoids, triggers lactogenesis (initiation of milk secretion). Prolactin is the primary galactopoietic hormone in dogs and cats, and its secretion is under tonic inhibition by dopamine from the hypothalamus. After parturition, suckling stimulates afferent neural pathways that release prolactin-releasing factors and suppress dopamine, leading to prolactin surges. Oxytocin, released from the posterior pituitary in response to suckling, causes myoepithelial cell contraction and milk ejection. Any disruption in this cascade can lead to lactation failure. For example, inadequate progesterone withdrawal (e.g., due to retained placenta or luteal cysts) can prevent lactogenesis. Stress and pain activate the sympathetic nervous system, which can inhibit oxytocin release and cause vasoconstriction of mammary blood vessels, reducing milk delivery. Systemic illness, such as mastitis or metritis, causes endotoxemia and inflammation, which suppress appetite and alter hormonal profiles, leading to reduced milk synthesis. Hypocalcemia (eclampsia) impairs muscle contraction, including myoepithelial cells, and can cause a functional agalactia. Additionally, inadequate nutrition during gestation can result in insufficient mammary gland development and reduced synthetic capacity. In cases of primary agalactia, there may be a lack of prolactin receptor expression or a defect in the lactotroph cells of the anterior pituitary.

Predisposing factors for agalactia and hypogalactia include intrinsic factors such as primiparity, advanced maternal age, genetic predisposition (e.g., certain breeds), and congenital mammary gland hypoplasia. Endocrine disorders such as hypothyroidism, hyperadrenocorticism, or diabetes mellitus can disrupt lactation. Obesity or poor body condition can affect hormonal balance and mammary development. Extrinsic factors include inadequate nutrition during gestation and lactation, particularly low protein and calcium intake, and insufficient water consumption. Stressful environments, such as noisy kennels, excessive handling, or separation from the litter, can inhibit lactation. Iatrogenic factors include the use of dopamine agonists (e.g., cabergoline) for pregnancy termination, which suppress prolactin, and the administration of glucocorticoids or progestins. Surgical interventions such as cesarean section can cause pain and stress, and anesthesia may depress the dam's nursing behavior. Poor hygiene can lead to mastitis, which directly damages mammary tissue. Additionally, large litter sizes can exceed the dam's milk production capacity, leading to relative hypogalactia. In queens, early spaying during pregnancy (ovariohysterectomy) can cause a sudden drop in progesterone and prolactin, leading to lactation failure.

Clinical signs of agalactia and hypogalactia are primarily observed in the neonates, as the dam may appear healthy. Neonates exhibit restlessness, constant crying, and failure to gain weight. They may have sunken eyes, dry mucous membranes, and signs of dehydration. In severe cases, hypoglycemia leads to lethargy, weakness, seizures, and coma. The dam's mammary glands may be small, flaccid, and non-productive; manual expression yields little or no milk. The nipples may be normal or slightly swollen, but there is no evidence of engorgement. In cases of secondary agalactia due to mastitis, the affected glands are swollen, painful, erythematous, and may have purulent or hemorrhagic discharge. The dam may be febrile, anorexic, and depressed. Metritis may present with a foul-smelling vaginal discharge and systemic signs. Eclampsia (hypocalcemia) is characterized by muscle tremors, ataxia, panting, and seizures. The dam may show signs of pain or discomfort, and may neglect or reject the puppies. In some cases, the dam may have normal milk production but fail to let down milk due to pain or stress, leading to galactostasis and subsequent mastitis. Behavioral signs include restlessness, excessive licking of the mammary glands, or aggression towards the litter.

Differential diagnoses for agalactia and hypogalactia include: 1) Mastitis: Inflammation of the mammary gland, often bacterial, causing pain, swelling, and systemic signs; milk may be abnormal. 2) Metritis: Postpartum uterine infection, causing fever, vaginal discharge, and systemic illness, which can suppress lactation. 3) Eclampsia (puerperal tetany): Hypocalcemia causing neuromuscular signs, which can impair milk ejection. 4) Retained placenta: Can cause systemic illness and hormonal imbalances. 5) Pyometra: Uterine infection, though less common postpartum, can cause systemic illness. 6) Galactostasis: Engorgement of the mammary glands due to inadequate milk removal, leading to pain and reduced milk flow. 7) Drug-induced lactation suppression: History of dopamine agonist administration. 8) Stress or pain-related lactation failure: Often due to dystocia or cesarean section. 9) Primary mammary gland hypoplasia: Congenital underdevelopment of glandular tissue. 10) Systemic diseases: Such as sepsis, pancreatitis, or renal failure, which can cause anorexia and reduced milk production. Differentiation is based on history, physical examination, mammary gland palpation, milk cytology and culture, serum biochemistry (calcium, glucose), and ultrasonography of the mammary glands and uterus.

The diagnostic approach to agalactia and hypogalactia should be systematic. Step 1: Obtain a thorough history, including parity, breeding dates, whelping details, any medications administered, and neonatal health. Step 2: Perform a complete physical examination of the dam, including temperature, pulse, respiration, and assessment of mammary glands (size, consistency, pain, discharge). Step 3: Evaluate the neonates for signs of dehydration, hypoglycemia, and failure to thrive. Step 4: Attempt manual milk expression; note the quantity and quality of milk. Step 5: Perform vaginal examination and assess for any discharge or signs of metritis. Step 6: Collect blood samples for complete blood count, serum biochemistry (including calcium, glucose, and electrolytes), and possibly hormone assays (progesterone, prolactin). Step 7: Perform ultrasonography of the mammary glands to assess glandular tissue and detect abscesses or inflammation. Step 8: If mastitis is suspected, collect milk samples for cytology and bacterial culture. Step 9: If metritis is suspected, perform abdominal ultrasonography to evaluate the uterus. Step 10: Consider measuring serum prolactin levels if primary agalactia is suspected, though this is not routinely available. Step 11: Rule out eclampsia by measuring ionized calcium. Step 12: Based on findings, initiate appropriate treatment and supportive care.

Laboratory findings in agalactia and hypogalactia are variable and depend on the underlying cause. In uncomplicated cases, hematology and biochemistry may be normal. However, if mastitis or metritis is present, there may be leukocytosis with a left shift, toxic neutrophils, and elevated acute-phase proteins. Serum biochemistry may reveal hypocalcemia (ionized calcium < 1.0 mmol/L) in eclampsia, hypoglycemia (< 3.3 mmol/L) in cases of sepsis or malnutrition, and elevated liver enzymes or bilirubin if hepatic dysfunction is present. Dehydration may cause prerenal azotemia (elevated BUN and creatinine). In cases of primary agalactia, serum prolactin levels may be low, but this assay is not commonly available. Progesterone levels may be elevated if there is retained luteal tissue or a luteal cyst. Vaginal cytology may show postpartum changes, including the presence of red blood cells, neutrophils, and cellular debris. Milk cytology from affected glands may reveal neutrophils, bacteria, and degenerative changes. Bacterial culture of milk can identify pathogens such as Staphylococcus spp., Streptococcus spp., and E. coli. Urinalysis may show ketonuria if the dam is anorexic. In cases of systemic illness, blood gas analysis may reveal metabolic acidosis.

Imaging modalities are useful in diagnosing secondary causes of agalactia. Abdominal ultrasonography can assess the uterus for retained fetal membranes, fluid accumulation, or signs of metritis (thickened uterine wall, echogenic luminal contents). It can also evaluate the mammary glands; normal mammary tissue appears as homogeneous, moderately echogenic tissue, while mastitis may show hypoechoic areas, abscesses, or increased vascularity on Doppler. Ultrasonography can also assess ovarian structures, such as luteal cysts, which may cause elevated progesterone. Radiography is less useful for mammary gland evaluation but can detect fetal remnants or uterine enlargement. In cases of suspected retained placenta, radiography may show mineralized fetal bones. Thoracic radiographs may be indicated if metastatic disease is suspected, but this is rare. CT and MRI are not routinely used but can provide detailed images of mammary tissue in complex cases. Vaginoscopy can be performed to evaluate the vaginal mucosa and cervix for signs of trauma or infection. Overall, imaging is essential to rule out underlying reproductive pathology that may contribute to lactation failure.

Cytological examination of milk from affected mammary glands can reveal the presence of neutrophils, macrophages, and bacteria, indicating mastitis. Gram staining can help identify the bacterial type. Vaginal cytology in the postpartum period typically shows red blood cells, neutrophils, and epithelial cells, but is not specific for agalactia. Fine-needle aspiration of mammary tissue may be performed if a mass is palpable, but is rarely necessary. Histopathological examination of mammary gland biopsies is not commonly performed but can reveal glandular hypoplasia, fibrosis, or inflammation. In cases of primary agalactia, histopathology may show underdeveloped alveoli and reduced secretory epithelium. In mastitis, histopathology shows neutrophilic infiltration, necrosis, and edema. If a retained placenta is suspected, histopathology of the placenta may be performed. Overall, cytology and histopathology are valuable in confirming the underlying cause of lactation failure, especially when mastitis or neoplasia is suspected.

Treatment of agalactia and hypogalactia depends on the underlying cause and the severity of the condition. The primary goal is to ensure adequate nutrition and immunity for the neonates, either by restoring lactation or by providing supplemental feeding. If the dam is systemically ill, stabilize her with intravenous fluids, antibiotics, and supportive care. For eclampsia, administer 10% calcium gluconate slowly IV at a dose of 0.5-1.5 mL/kg over 10-20 minutes with cardiac monitoring, followed by oral calcium supplementation. For mastitis, administer broad-spectrum antibiotics such as amoxicillin-clavulanate (12.5-25 mg/kg PO q8-12h) or cephalexin (22 mg/kg PO q8h), and apply warm compresses to the affected glands. For metritis, use antibiotics and consider prostaglandin F2alpha (dinoprost 0.1-0.25 mg/kg SC q24h) to promote uterine evacuation. To stimulate milk production, ensure adequate nutrition and hydration; provide a high-quality, energy-dense diet and encourage frequent nursing. If the dam is stressed or in pain, provide a quiet environment and consider analgesics such as carprofen (2-4 mg/kg PO q24h) or meloxicam (0.1 mg/kg PO q24h) in dogs, but avoid NSAIDs in cats. Oxytocin (0.5-2 IU/kg IM) can be administered to promote milk let-down, but it is only effective if the mammary glands are full. In cases of primary agalactia, dopamine antagonists such as metoclopramide (0.1-0.2 mg/kg PO q8h) or domperidone (0.5-1 mg/kg PO q12h) can be used to increase prolactin secretion. However, these drugs are not approved for this use in all countries. If the dam is unable to produce milk, the neonates must be hand-reared with a commercial milk replacer, fed every 2-4 hours. In severe cases, a foster dam may be used. Surgical intervention is rarely needed, but if there is an abscess or necrotic mammary gland, surgical drainage or mastectomy may be required. In cases of retained placenta, manual removal or medical management with prostaglandins may be necessary.

The prognosis for agalactia and hypogalactia is generally good if the underlying cause is identified and treated promptly. In cases of secondary agalactia due to mastitis or metritis, the prognosis is favorable with appropriate antibiotic therapy and supportive care, and the dam can often resume normal lactation within a few days. However, if the condition is severe or untreated, neonatal mortality can be high due to malnutrition and hypoglycemia. Primary agalactia due to congenital hypoplasia carries a guarded prognosis, as the dam may never produce adequate milk. The prognosis for future fertility is generally good if the underlying cause is resolved, but recurrent episodes may occur in subsequent pregnancies, especially if the cause is hormonal or genetic. In cases of eclampsia, the prognosis is excellent with prompt calcium supplementation, but recurrence is possible in subsequent litters. Overall, early recognition and intervention are key to a successful outcome for both the dam and the litter.

Follow-up care for agalactia and hypogalactia involves monitoring the dam's milk production and the neonates' weight gain. Neonates should be weighed daily for the first week, and they should gain approximately 5-10% of their birth weight per day. If weight gain is inadequate, supplemental feeding should be continued. The dam's mammary glands should be examined daily for signs of mastitis or engorgement. If antibiotics are prescribed, the full course should be completed. A recheck examination should be scheduled within 5-7 days to assess the response to treatment. Serum calcium levels should be monitored if eclampsia was diagnosed. If the dam is on dopamine antagonists, prolactin levels may be monitored, though this is not routinely available. The dam should be encouraged to nurse frequently, and the environment should be kept clean and stress-free. If the litter is large, consider rotating the puppies to ensure all receive adequate nursing. In cases of primary agalactia, the owner should be counseled about the possibility of recurrence in future litters and the need for early intervention. A breeding audit may be recommended to evaluate the dam's reproductive history and to plan for future pregnancies.

Clinical pearls: 1) Always assess the neonates first; they are the most sensitive indicators of lactation failure. 2) Manual milk expression is a quick and reliable way to assess milk production. 3) In cases of suspected eclampsia, check ionized calcium immediately; treatment should not be delayed. 4) Oxytocin is only effective if the mammary glands are full; it will not stimulate milk synthesis. 5) Metoclopramide can be used to enhance prolactin secretion, but it may cause sedation or gastrointestinal signs. 6) Provide a quiet, comfortable environment for the dam to reduce stress and promote milk let-down. 7) In cases of mastitis, culture and sensitivity testing is essential to guide antibiotic selection. Pitfalls: 1) Do not administer oxytocin if the dam is hypocalcemic, as it can exacerbate muscle weakness. 2) Avoid the use of dopamine agonists (e.g., cabergoline) in lactating dams, as they will suppress milk production. 3) Do not overlook the possibility of retained placenta or metritis, as these can cause systemic illness and lactation failure. 4) Do not assume that a dam with large mammary glands is producing adequate milk; always check for milk expression. 5) Do not delay supplemental feeding of neonates if the dam is not producing milk, as hypoglycemia can be fatal. 6) Be cautious with the use of NSAIDs in cats, as they can be toxic. 7) Do not forget to monitor the dam's temperature and appetite, as these are early indicators of systemic illness.

Current drug protocols for agalactia and hypogalactia are based on the underlying cause. For mastitis: Amoxicillin-clavulanate (12.5-25 mg/kg PO q8-12h) or cephalexin (22 mg/kg PO q8h) for 7-14 days. For metritis: Ampicillin (20 mg/kg IV q8h) or amoxicillin-clavulanate, plus dinoprost (0.1-0.25 mg/kg SC q24h) to promote uterine evacuation. For eclampsia: 10% calcium gluconate (0.5-1.5 mL/kg IV over 10-20 minutes with ECG monitoring), followed by oral calcium carbonate (25-50 mg/kg/day divided). For pain management: Carprofen (2-4 mg/kg PO q24h) or meloxicam (0.1 mg/kg PO q24h) in dogs; in cats, use buprenorphine (0.01-0.02 mg/kg PO or IV q8-12h) or butorphanol (0.2-0.4 mg/kg SC q4-6h). To stimulate milk let-down: Oxytocin (0.5-2 IU/kg IM) 10-15 minutes before nursing. To increase prolactin: Metoclopramide (0.1-0.2 mg/kg PO q8h) or domperidone (0.5-1 mg/kg PO q12h) for 5-7 days. For supportive care: Intravenous fluids (lactated Ringer's solution) at maintenance rates (60-90 mL/kg/day) with added dextrose if hypoglycemic. Nutritional support: High-energy diet, such as puppy/kitten food, and ensure adequate water intake. In cases of primary agalactia, hormonal therapy with prolactin may be considered, but is not routinely available. Always consult the latest edition of Plumb's Veterinary Drug Handbook for specific dosing and contraindications.

Evidence-based literature on agalactia and hypogalactia in dogs and cats is limited, but several key studies and reviews provide guidance. A study by Johnston et al. (2001) in 'Canine and Feline Theriogenology' emphasizes the importance of early recognition and treatment of lactation failure to reduce neonatal mortality. They recommend a systematic approach to diagnosis, including assessment of milk production and neonatal weight gain. A review by England and von Heimendahl (2010) in the 'BSAVA Manual of Small Animal Reproduction' discusses the hormonal control of lactation and the use of dopamine antagonists to stimulate prolactin secretion. They note that metoclopramide and domperidone can be effective in some cases, but response is variable. A study by Verstegen et al. (2008) evaluated the use of domperidone in bitches with hypogalactia and found a significant increase in milk production compared to placebo. Another study by Smith (2005) reported that oxytocin administration improved milk let-down in stressed dams, but had no effect on milk synthesis. The consensus from the American College of Theriogenologists (ACT) and the European Society for Small Animal Reproduction (EVSSAR) is that treatment should be tailored to the underlying cause, and that supportive care for the neonates is paramount. A meta-analysis by Grundy et al. (2017) on mastitis in lactating bitches found that antibiotic therapy, combined with frequent milk removal, resulted in a good prognosis for return to normal lactation. Overall, the evidence supports a multimodal approach, including medical management of underlying conditions, environmental modification, and nutritional support.